Sage Therapeutics (SAGE)
(Delayed Data from NSDQ)
$7.59 USD
+0.07 (0.93%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $7.59 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SAGE 7.59 +0.07(0.93%)
Will SAGE be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for SAGE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SAGE
Biogen Stock Declines 20.9% Year to Date: Time to Sell?
Sage Therapeutics (SAGE) Down 17.1% Since Last Earnings Report: Can It Rebound?
SAGE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Biogen (BIIB) Q2 Earnings & Sales Beat, 2024 Guidance Raised
Sage Therapeutics (SAGE) Q2 Loss Wider Than Expected, Sales Rise
Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Tops Revenue Estimates
Other News for SAGE
Sage Therapeutics files automatic mixed securities shelf
Sage Therapeutics files prospectus to offer $250M of common stock
Sage Therapeutics files for $250M of common stock
Sage Potash Shares to Resume Trading
Sage Potash Announces Equipment Purchase and Financing